Fruquintinib is a novel oral small-molecule tyrosine kinase inhibitor (TKI) that selectively targets vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3 [7]. Its primary anti-tumour mechanism lies in inhibition of angiogenesis, a process critical for tumour growth and metastasis. Here, FLT4 is linked to neoplasm.